JP2011528551A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528551A5
JP2011528551A5 JP2011518935A JP2011518935A JP2011528551A5 JP 2011528551 A5 JP2011528551 A5 JP 2011528551A5 JP 2011518935 A JP2011518935 A JP 2011518935A JP 2011518935 A JP2011518935 A JP 2011518935A JP 2011528551 A5 JP2011528551 A5 JP 2011528551A5
Authority
JP
Japan
Prior art keywords
dab
antigen
seq
disease
polypeptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011518935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528551A (ja
JP5675608B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/050985 external-priority patent/WO2010009391A1/en
Publication of JP2011528551A publication Critical patent/JP2011528551A/ja
Publication of JP2011528551A5 publication Critical patent/JP2011528551A5/ja
Application granted granted Critical
Publication of JP5675608B2 publication Critical patent/JP5675608B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011518935A 2008-07-18 2009-07-17 Cd28結合のための一価組成物および使用方法 Expired - Fee Related JP5675608B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US61/082,078 2008-07-18
US16212109P 2009-03-20 2009-03-20
US61/162,121 2009-03-20
PCT/US2009/050985 WO2010009391A1 (en) 2008-07-18 2009-07-17 Compositions monovalent for cd28 binding and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014261305A Division JP5876134B2 (ja) 2008-07-18 2014-12-24 Cd28結合のための一価組成物および使用方法

Publications (3)

Publication Number Publication Date
JP2011528551A JP2011528551A (ja) 2011-11-24
JP2011528551A5 true JP2011528551A5 (cg-RX-API-DMAC7.html) 2012-08-30
JP5675608B2 JP5675608B2 (ja) 2015-02-25

Family

ID=41226147

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011518935A Expired - Fee Related JP5675608B2 (ja) 2008-07-18 2009-07-17 Cd28結合のための一価組成物および使用方法
JP2014261305A Expired - Fee Related JP5876134B2 (ja) 2008-07-18 2014-12-24 Cd28結合のための一価組成物および使用方法
JP2016009024A Expired - Fee Related JP6058833B2 (ja) 2008-07-18 2016-01-20 Cd28結合のための一価組成物および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014261305A Expired - Fee Related JP5876134B2 (ja) 2008-07-18 2014-12-24 Cd28結合のための一価組成物および使用方法
JP2016009024A Expired - Fee Related JP6058833B2 (ja) 2008-07-18 2016-01-20 Cd28結合のための一価組成物および使用方法

Country Status (29)

Country Link
US (6) US8168759B2 (cg-RX-API-DMAC7.html)
EP (2) EP2700651B1 (cg-RX-API-DMAC7.html)
JP (3) JP5675608B2 (cg-RX-API-DMAC7.html)
KR (2) KR101660057B1 (cg-RX-API-DMAC7.html)
CN (2) CN102159590A (cg-RX-API-DMAC7.html)
AR (1) AR072571A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009270726B2 (cg-RX-API-DMAC7.html)
CA (1) CA2731220C (cg-RX-API-DMAC7.html)
CL (2) CL2011000117A1 (cg-RX-API-DMAC7.html)
CO (1) CO6341641A2 (cg-RX-API-DMAC7.html)
CY (1) CY1121796T1 (cg-RX-API-DMAC7.html)
DK (2) DK2321352T3 (cg-RX-API-DMAC7.html)
EA (1) EA024585B1 (cg-RX-API-DMAC7.html)
ES (2) ES2730727T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160329T1 (cg-RX-API-DMAC7.html)
HU (2) HUE045249T2 (cg-RX-API-DMAC7.html)
IL (2) IL210413A (cg-RX-API-DMAC7.html)
LT (1) LT2700651T (cg-RX-API-DMAC7.html)
ME (1) ME02396B (cg-RX-API-DMAC7.html)
MX (1) MX2011000501A (cg-RX-API-DMAC7.html)
NZ (1) NZ590343A (cg-RX-API-DMAC7.html)
PE (2) PE20110385A1 (cg-RX-API-DMAC7.html)
PL (2) PL2700651T3 (cg-RX-API-DMAC7.html)
PT (2) PT2321352E (cg-RX-API-DMAC7.html)
RS (2) RS58904B1 (cg-RX-API-DMAC7.html)
SI (2) SI2700651T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900367T1 (cg-RX-API-DMAC7.html)
TW (2) TW201336510A (cg-RX-API-DMAC7.html)
WO (1) WO2010009391A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2011000501A (es) 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
CN104017778A (zh) * 2009-02-25 2014-09-03 内克斯特伊拉股份公司 不依赖信号序列的pIX噬菌体展示
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
US10654933B2 (en) * 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
US20170051059A1 (en) * 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
KR20170062505A (ko) 2014-09-30 2017-06-07 브리스톨-마이어스 스큅 컴퍼니 Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법
US20190086405A1 (en) 2016-03-16 2019-03-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
AU2019234183B2 (en) 2018-03-15 2025-12-18 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US12139537B2 (en) * 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
WO2020014143A1 (en) * 2018-07-08 2020-01-16 Specifica Inc. Antibody libraries with maximized antibody developability characteristics
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7474240B2 (ja) 2018-08-03 2024-04-24 ブリストル-マイヤーズ スクイブ カンパニー 抗薬物抗体を検出するための方法
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3938397A1 (en) 2019-03-14 2022-01-19 Biond Biologics Ltd. Small shedding blocking agents
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
US12612459B2 (en) 2019-12-02 2026-04-28 Biond Biologics Ltd. Methods of identifying agents that block MCD28 cleavage by MMPS
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
EP4097129A1 (en) * 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
KR20220152555A (ko) 2020-03-12 2022-11-16 비온드 바이오로직스 엘티디 증가된 안정성을 가진 쉐딩 차단제
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4399229A2 (en) * 2021-09-06 2024-07-17 Biond Biologics Ltd. Cd28 shedding blocking agents
EP4519326A4 (en) * 2022-05-04 2026-05-06 Janux Therapeutics Inc TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US6346274B1 (en) 1995-03-10 2002-02-12 Roche Diagnostics Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU766959B2 (en) 1998-04-20 2003-10-30 Genzyme Corporation Drug delivery of proteins from polymeric blends
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2000069907A1 (en) 1999-05-14 2000-11-23 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
EP1345969B1 (fr) * 2000-12-26 2010-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticorps anti-cd28
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
CA2462531A1 (en) 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
US8907065B2 (en) * 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
MX2011000501A (es) * 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
US20170051059A1 (en) * 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
KR20170062505A (ko) * 2014-09-30 2017-06-07 브리스톨-마이어스 스큅 컴퍼니 Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법

Similar Documents

Publication Publication Date Title
Lykhopiy et al. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity
JP4628792B2 (ja) 免疫疾患治療用ラパマイシン及びil−10
ME02396B (me) Smješe monovalentne za vezivanje sa cd28 i metodi upotrebe
Zhou et al. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease
US10800828B2 (en) Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
AU2014337367B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
Kim et al. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation
Choi et al. Current and emerging strategies for the prevention of graft-versus-host disease
Mishra et al. Inflammatory bowel disease: therapeutic limitations and prospective of the stem cell therapy
AU2025237926A1 (en) Nanoparticle compositions for sustained therapy
JP2024071445A5 (cg-RX-API-DMAC7.html)
Liu et al. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease
Kebriaei et al. Treatment of graft-versus-host-disease with mesenchymal stromal cells
JP2010505830A5 (cg-RX-API-DMAC7.html)
JP2018537962A5 (cg-RX-API-DMAC7.html)
WO2016168766A1 (en) Optimized chimeric receptor t cell switches and uses thereof
JP2013508392A5 (cg-RX-API-DMAC7.html)
CN108883180A (zh) Clec9a结合剂及其用途
KR20200047564A (ko) Clec9a 결합제 및 그의 용도
Kitagawa et al. Preclinical development of a WT1 oral cancer vaccine using a bacterial vector to treat castration-resistant prostate cancer
Yang et al. Therapeutic application of T regulatory cells in composite tissue allotransplantation
Mok et al. Recent advances and current state of immunotherapy in systemic lupus erythematosus
Ouyang et al. Recombinant protein Ag85B-Rv2660c-MPT70 promotes quality of BCG-induced immune response against Mycobacterium tuberculosis H37Ra
Cassano et al. Mesenchymal stem Cell therapy: Clinical progress and opportunities for advancement
JP2013508391A5 (cg-RX-API-DMAC7.html)